Date: 29th January 2021
Time: 09.50 AM Singapore Time / 02.50 AM CET
Title: A phase II study of the oral selective AXL inhibitor bemcentinib with pembrolizumab in refractory patients with advanced NSCLC
Presenting Author: Dr. Matthew G. Krebs PhD.
Session/Abstract ID: Immunotherapy (Phase II/III Trials) # 3647
The presentation can be found at www.bergenbio.com under Investors / Presentations